(AHCO) Adapthealth - Overview
Stock: CPAP, Insulin Pumps, Oxygen, Wheelchairs, Supplies
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 59.3% |
| Relative Tail Risk | -14.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.36 |
| Alpha | -8.75 |
| Character TTM | |
|---|---|
| Beta | 0.812 |
| Beta Downside | 0.841 |
| Drawdowns 3y | |
|---|---|
| Max DD | 71.45% |
| CAGR/Max DD | -0.28 |
Description: AHCO Adapthealth January 19, 2026
AdaptHealth Corp. (NASDAQ: AHCO) distributes a broad portfolio of home medical equipment (HME) and related services across the United States, serving Medicare, Medicaid, and commercial insurers. Its product suite includes sleep-therapy devices (CPAP/Bi-PAP), diabetes management tools (continuous glucose monitors, insulin pumps), chronic-care oxygen therapy, and a range of mobility and wound-care supplies.
Founded in 2012 and headquartered in Plymouth Meeting, Pennsylvania, the company operates within the Health Care Distributors sub-industry and derives the majority of its revenue from long-term contracts with acute-care facilities and post-acute discharge patients.
Key performance indicators from the latest filing show FY 2023 revenue of approximately $1.32 billion, with an operating margin near 5% and a 6% year-over-year increase in recurring home-care service contracts-reflecting the broader 5-6% CAGR growth in the U.S. home-health market driven by an aging population and expanding chronic-disease prevalence.
Economic drivers include Medicare reimbursement policy shifts (e.g., bundled payments for home oxygen therapy) and the ongoing migration of post-acute care from hospitals to the home setting, which together boost demand for AdaptHealth’s bundled equipment-plus-service offerings.
For a deeper quantitative assessment, you might explore the company’s metrics on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income: 80.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -0.27 > 1.0 |
| NWC/Revenue: 1.90% < 20% (prev 4.01%; Δ -2.11% < -1%) |
| CFO/TA 0.13 > 3% & CFO 569.0m > Net Income 80.2m |
| Net Debt (1.82b) to EBITDA (651.0m): 2.80 < 3 |
| Current Ratio: 1.08 > 1.5 & < 3 |
| Outstanding Shares: last quarter (137.2m) vs 12m ago 0.50% < -2% |
| Gross Margin: 12.24% > 18% (prev 0.19%; Δ 1206 % > 0.5%) |
| Asset Turnover: 64.36% > 50% (prev 73.02%; Δ -8.65% > 0%) |
| Interest Coverage Ratio: 2.38 > 6 (EBITDA TTM 651.0m / Interest Expense TTM 111.0m) |
Altman Z'' -0.11
| A: 0.01 (Total Current Assets 724.8m - Total Current Liabilities 670.7m) / Total Assets 4.38b |
| B: -0.12 (Retained Earnings -530.2m / Total Assets 4.38b) |
| C: 0.06 (EBIT TTM 264.6m / Avg Total Assets 4.43b) |
| D: -0.19 (Book Value of Equity -529.6m / Total Liabilities 2.76b) |
| Altman-Z'' Score: -0.11 = B |
Beneish M -2.62
| DSRI: 1.18 (Receivables 412.5m/401.2m, Revenue 2.85b/3.26b) |
| GMI: 1.53 (GM 12.24% / 18.75%) |
| AQI: 0.98 (AQ_t 0.69 / AQ_t-1 0.71) |
| SGI: 0.87 (Revenue 2.85b / 3.26b) |
| TATA: -0.11 (NI 80.2m - CFO 569.0m) / TA 4.38b) |
| Beneish M-Score: -2.62 (Cap -4..+1) = A |
What is the price of AHCO shares?
Over the past week, the price has changed by +5.97%, over one month by +5.65%, over three months by +10.82% and over the past year by +10.25%.
Is AHCO a buy, sell or hold?
- StrongBuy: 5
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the AHCO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 13.4 | 25.6% |
| Analysts Target Price | 13.4 | 25.6% |
| ValueRay Target Price | 10 | -5.7% |
AHCO Fundamental Data Overview February 03, 2026
P/E Forward = 9.8619
P/S = 0.4181
P/B = 0.8422
Revenue TTM = 2.85b USD
EBIT TTM = 264.6m USD
EBITDA TTM = 651.0m USD
Long Term Debt = 1.74b USD (from longTermDebt, last quarter)
Short Term Debt = 60.1m USD (from shortTermDebt, last quarter)
Debt = 1.90b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.82b USD (from netDebt column, last quarter)
Enterprise Value = 3.18b USD (1.36b + Debt 1.90b - CCE 80.4m)
Interest Coverage Ratio = 2.38 (Ebit TTM 264.6m / Interest Expense TTM 111.0m)
EV/FCF = 14.94x (Enterprise Value 3.18b / FCF TTM 213.2m)
FCF Yield = 6.69% (FCF TTM 213.2m / Enterprise Value 3.18b)
FCF Margin = 7.48% (FCF TTM 213.2m / Revenue TTM 2.85b)
Net Margin = 2.81% (Net Income TTM 80.2m / Revenue TTM 2.85b)
Gross Margin = 12.24% ((Revenue TTM 2.85b - Cost of Revenue TTM 2.50b) / Revenue TTM)
Gross Margin QoQ = 18.51% (prev -9.11%)
Tobins Q-Ratio = 0.73 (Enterprise Value 3.18b / Total Assets 4.38b)
Interest Expense / Debt = 1.33% (Interest Expense 25.4m / Debt 1.90b)
Taxrate = 29.16% (10.6m / 36.4m)
NOPAT = 187.4m (EBIT 264.6m * (1 - 29.16%))
Current Ratio = 1.08 (Total Current Assets 724.8m / Total Current Liabilities 670.7m)
Debt / Equity = 1.18 (Debt 1.90b / totalStockholderEquity, last quarter 1.62b)
Debt / EBITDA = 2.80 (Net Debt 1.82b / EBITDA 651.0m)
Debt / FCF = 8.55 (Net Debt 1.82b / FCF TTM 213.2m)
Total Stockholder Equity = 1.59b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.81% (Net Income 80.2m / Total Assets 4.38b)
RoE = 5.06% (Net Income TTM 80.2m / Total Stockholder Equity 1.59b)
RoCE = 7.95% (EBIT 264.6m / Capital Employed (Equity 1.59b + L.T.Debt 1.74b))
RoIC = 5.41% (NOPAT 187.4m / Invested Capital 3.46b)
WACC = 4.26% (E(1.36b)/V(3.26b) * Re(8.91%) + D(1.90b)/V(3.26b) * Rd(1.33%) * (1-Tc(0.29)))
Discount Rate = 8.91% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.57%
[DCF Debug] Terminal Value 87.46% ; FCFF base≈219.6m ; Y1≈248.1m ; Y5≈335.1m
Fair Price DCF = 59.40 (EV 9.87b - Net Debt 1.82b = Equity 8.04b / Shares 135.4m; r=5.90% [WACC]; 5y FCF grow 15.08% → 2.90% )
EPS Correlation: 3.91 | EPS CAGR: -1.08% | SUE: -0.51 | # QB: 0
Revenue Correlation: 7.10 | Revenue CAGR: 4.24% | SUE: 0.19 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.04 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=5
EPS next Year (2026-12-31): EPS=0.99 | Chg30d=+0.000 | Revisions Net=-2 | Growth EPS=+39.5% | Growth Revenue=+6.5%